We agree with the comments by Chow and Szeto on the use of tranexamic acid to improve hemostasis during dental procedures. Although beyond the scope of our review, the appropriate use of local measures, which may include local pressure, tranexamic acid, tannic acid (biting on tea bags), oxidized cellulose gauze, gelatin sponges, or topical thrombin, is recommended when performing dental surgery on anticoagulated patients.
We appreciate the comments by Kearon and Hirsh on the efficacy of heparin and LMWH therapy on prevention of arterial thromboembolic events. They cite recent studies as indicating that therapy with heparin or LMWH is not as efficacious as warfarin in preventing arterial thromboembolism. The overview of randomized trials listed in favor of their argument, however, is not relevant to the interruption of oral anticoagulation.1 The principal data are based on the Heparin in Acute Embolic Stroke Trial,2 which randomized patients after acute stroke associated with atrial fibrillation to aspirin or therapeutic-dose LMWH therapy. The trial found no difference in recurrent ischemic strokes at 14 days. There are several reasons this trial does not provide information on the efficacy of heparin or LMWH therapy in decreasing the incidence of perioperative thromboembolic events. First, since the study examines treatment of an acute condition, it may not be justified to extrapolate the outcomes to long-term management. Second, recurrent stroke was defined as "persistent worsening of the original deficit after the first 48 hours," rather than stroke in a new vascular distribution. The authors of the overview point out that the lack of positive findings for LMWH therapy may have been due to "inclusion of nonthrombotic causes of worsening among events." Lastly, patients in the LMWH group were denied aspirin, which is established as an effective treatment for ischemic stroke. Kearon and Hirsh also cite a review article discussing the use of LMWH for pregnant women with mechanical heart valves.3 The authors of this article discuss the limited nature of the evidence that LMWH therapy may not be efficacious and conclude that
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.